Last reviewed · How we verify

BNP7787 — Competitive Intelligence Brief

BNP7787 (BNP7787) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytoprotective agent / Cisplatin protectant. Area: Oncology.

phase 3 Cytoprotective agent / Cisplatin protectant Cisplatin (indirect; forms inactivating complex) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BNP7787 (BNP7787) — Alliance for Clinical Trials in Oncology. BNP7787 is a cytoprotective agent that binds to and inactivates cisplatin, reducing its nephrotoxicity and neurotoxicity while preserving anti-tumor efficacy.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BNP7787 TARGET BNP7787 Alliance for Clinical Trials in Oncology phase 3 Cytoprotective agent / Cisplatin protectant Cisplatin (indirect; forms inactivating complex)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytoprotective agent / Cisplatin protectant class)

  1. Alliance for Clinical Trials in Oncology · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BNP7787 — Competitive Intelligence Brief. https://druglandscape.com/ci/bnp7787. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: